INNATE PHARMA (IPH) 1.58 EUR (-0.75%) | Healthcare Euronext / Paris

Innate Pharma is a biotechnology company focused on immunotherapy and antibody research, primarily in the treatment of cancer.

biotechnology

Momentum appears positive in the very short term, but within an overall still fragile and clearly deteriorated backdrop over longer horizons. Strategically, this suggests a possible technical rebound, without changing the highly speculative profile that depends above all on clinical, regulatory, or partnership milestones. The lack of visible recent news currently limits fundamental conviction.

INNATE PHARMA

Trend Analysis of INNATE PHARMA

Want to see the full analysis?